Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
Review

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

T. Sagawa Masahiro Hirakawa H. Nagashima K. Fujikawa
Sep 2026 · Journal of Gastrointestinal Cancer · Vol 57 · 0 citations · 47 references
Medicine

TL;DR

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Sep 2026

Targeting KRAS-Mutant Lung Cancers.

KRAS mutations are the most common oncogenic driver alterations in non-small cell lung cancer (NSCLC) and define biologically heterogeneous diseases shaped by mutation subtype, co-mutation patterns, and immune contexture. Recent advances in structural and chemical biology have transformed KRAS from an undruggable targe...

E. Garbo, P. Scaparone, Hui Jing Hoe et al. · 0 citations
Review Aug 2026

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions

The biologic rationale, current clinical evidence, practical guideline-based positioning, practical guideline-based positioning, toxicity management considerations, resistance mechanisms, and emerging therapeutic strategies for KRAS G12C-mutated mCRC are summarized.

T. Sagawa, H. Nagashima, K. Fujikawa · 0 citations
Review Sep 2026

Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.

Srijita Chatterjee, S. Arya, Nidhi Sharma et al. · 0 citations
Review Aug 2026

Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.

This review summarizes recent progress in KRAS G12D-targeted inhibitors and degraders, highlighting current challenges and future opportunities for improving KRAS-directed cancer treatment.

Eun-Hyoung Jeon, Jaewon Song, Taebo Sim · 0 citations
Review Aug 2026

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms

KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.

A. Kapoor, Bipinesh Sansar, Anuj Gupta et al. · 0 citations
Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer.

INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as 'undrugg...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.